Omnipod 5自动胰岛素输送系统在2型糖尿病成人中的安全性与有效性:从注射治疗到混合闭环治疗
这项多中心门诊可行性试验纳入24例血糖控制不佳的2型糖尿病成人,先进行2周标准治疗下的CGM监测,随后转为8周Omnipod 5自动胰岛素输送(AID)治疗。AID期间血糖≥250 mg/dL的时间百分比降低16.9%±16.2%,HbA1c降低1.3%±0.7%,目标范围内时间(TIR)增加21.9%±15.2%,而血糖<54 mg/dL的时间无显著变化。作者认为该可行性试验结果支持在这一人群中进一步评估该技术。
要点
- AID使血糖≥250 mg/dL的时间百分比降低16.9%±16.2%(P<0.0001)。
- HbA1c降低1.3%±0.7%,TIR增加21.9%±15.2%(均P<0.0001)。
- 血糖<54 mg/dL的时间在标准治疗与AID期间均较低,无显著变化(P=0.4543)。
核心结论
- 这项在血糖控制不佳的2型糖尿病成人中进行的AID可行性试验结果,支持在这一人群中进一步评估该技术。
研究设计与样本
- 多中心门诊可行性试验,纳入24例既往使用基础胰岛素或基础-餐时胰岛素注射(联合或不联合CGM)且基线HbA1c≥8%(≥64 mmol/mol)的2型糖尿病成人。
- 参与者先完成2周标准治疗下的CGM传感器数据收集(既往未使用CGM者采用盲法),随后转为8周AID治疗。
- 既往仅使用基础胰岛素注射的参与者在开始AID前先使用手动模式2周。
- 降糖药物由临床医生酌情继续使用。
主要发现
- 参与者(N=24)平均(±SD)年龄61±8岁,基线HbA1c 9.4%±0.9%(79±10 mmol/mol),糖尿病病程19±9年。
- AID期间血糖≥250 mg/dL的时间百分比降低16.9%±16.2%(P<0.0001)。
- 血糖<54 mg/dL的时间百分比在标准治疗与AID期间均较低(中位数[四分位距] 0.0%[0.00%, 0.06%] vs. 0.00%[0.00%, 0.03%];P=0.4543)。
- HbA1c(±SD)降低1.3%±0.7%(14±8 mmol/mol;P<0.0001),TIR增加21.9%±15.2%(P<0.0001)。
- AID期间每日总胰岛素剂量或BMI无显著变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Automated insulin delivery (AID) has rarely been studied in adults with type 2 diabetes. We tested the feasibility of using AID for type 2 diabetes with the Omnipod 5 System in a multicenter outpatient trial. RESEARCH DESIGN AND METHODS: Participants previously were using either basal-only or basal-bolus insulin injections, with or without the use of a continuous glucose monitor (CGM), and had a baseline HbA1c ≥8% (≥64 mmol/mol). Participants completed 2 weeks of CGM sensor data collection (blinded for those not previously using CGM) with their standard therapy (ST), then transitioned to 8 weeks of AID. Participants who previously used basal-only injections used the AID system in manual mode for 2 weeks before starting AID. Antihyperglycemic agents were continued at clinician discretion. Primary safety outcomes were percentage of time with sensor glucose ≥250 mg/dL and <54 mg/dL during AID. Additional outcomes included HbA1c and time in target range (TIR) (70-180 mg/dL). RESULTS: Participants (N = 24) had a mean (± SD) age of 61 ± 8 years, baseline HbA1c of 9.4% ± 0.9% (79 ± 10 mmol/mol), and diabetes duration of 19 ± 9 years. Percentage of time with sensor glucose ≥250 mg/dL decreased with AID by 16.9% ± 16.2% (P < 0.0001), whereas percentage of time at <54 mg/dL remained low during both ST and AID (median [interquartile range] 0.0% [0.00%, 0.06%] vs. 0.00% [0.00%, 0.03%]; P = 0.4543). HbA1c (± SD) decreased by 1.3% ± 0.7% (14 ± 8 mmol/mol; P < 0.0001) and TIR increased by 21.9% ± 15.2% (P < 0.0001) without a significant change in total daily insulin or BMI with AID. CONCLUSIONS: Findings from this feasibility trial of AID in adults with type 2 diabetes with suboptimal glycemic outcomes justify further evaluation of this technology in this population.
引用
- Davis GM, Peters AL, Bode BW, et al. Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes: From Injections to Hybrid Closed-Loop Therapy. Diabetes Care. 2023. PMID: 36787903. doi:10.2337/dc22-1915
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。